Edition:
United Kingdom

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

148.29USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$148.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,334
52-wk High
$182.30
52-wk Low
$105.19

Latest Key Developments (Source: Significant Developments)

Beigene Granted Approval To Transition From The Biotech Chapter Of The Hong Kong Stock Exchange To A General Listing
Friday, 28 Jun 2019 

June 28 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE GRANTED APPROVAL TO TRANSITION FROM THE BIOTECH CHAPTER OF THE HONG KONG STOCK EXCHANGE TO A GENERAL LISTING.BEIGENE LTD - "B" MARKER WILL BE REMOVED FROM COMPANY'S STOCK SYMBOL IN HKEX.BEIGENE LTD - COMPANY'S ORDINARY SHARES MAY BECOME ELIGIBLE FOR LISTING IN HANG SENG INDICES..  Full Article

BeiGene Presents Phase 2 Results Of Zanubrutinib In Patients With Leukemia Or Lymphoma
Thursday, 20 Jun 2019 

June 20 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE PRESENTS PIVOTAL PHASE 2 CLINICAL RESULTS OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AT THE 15TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML).BEIGENE LTD - ZANUBRUTINIB TOLERABILITY WAS GENERALLY CONSISTENT WITH PREVIOUS REPORTS.BEIGENE LTD - THREE PATIENTS HAD TEAES LEADING TO DEATH; THESE WERE DETERMINED UNLIKELY OR UNRELATED TO ZANUBRUTINIB TREATMENT.BEIGENE LTD - ORR BY IRC WAS 84.6%; COMPLETE RESPONSE (CR) RATE WAS 3.3%.BEIGENE LTD - AS OF DEC 14, 2018 DATA CUTOFF, 75 PATIENTS (82.4%) REMAINED ON STUDY TREATMENT.  Full Article

Beigene Announces Acceptance Of Supplemental Import Drug Application In China For Abraxane
Friday, 31 May 2019 

May 30 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL IMPORT DRUG APPLICATION IN CHINA FOR ABRAXANE® IN METASTATIC PANCREATIC CANCER.BEIGENE LTD- CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION HAS ACCEPTED SUPPLEMENTAL IMPORT DRUG APPLICATION FOR ABRAXANE.  Full Article

Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
Friday, 10 May 2019 

May 10 (Reuters) - Beigene Ltd <6160.HK>::QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION.QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION.  Full Article

BeiGene Q1 Loss Per Share $0.22
Thursday, 9 May 2019 

May 9 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018.QTRLY LOSS PER SHARE $0.22.  Full Article

Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
Monday, 29 Apr 2019 

April 29 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING.BEIGENE LTD SAYS GENERAL MANAGER OF CHINA AND PRESIDENT XIAOBIN WU'S TOTAL COMPENSATION FOR FY 2018 WAS $21.5 MILLION.BEIGENE LTD - RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 135:1.  Full Article

Bioatla And Beigene Form Worldwide Collaboration To Develop And Commercialize Novel Conditionally Active Biologic Ctla-4 Therapy
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Beigene Ltd <6160.HK>::BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY.BIOATLA LLC - WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND A MILESTONE PAYMENT UPON REACHING DEFINED EARLY CLINICAL OBJECTIVES.BIOATLA - BEIGENE WILL HOLD A CO-EXCLUSIVE LICENSE WITH BIOATLA TO DEVELOP AND MANUFACTURE PRODUCT CANDIDATE GLOBALLY.BIOATLA - IS ALSO ELIGIBLE TO RECEIVE UP TO $249 MILLION IN MILESTONE PAYMENTS.  Full Article

Beigene Reports Qtrly Loss Per Share Of $0.35
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52.BEIGENE LTD QTRLY LOSS PER SHARE $0.35.BEIGENE LTD QTRLY TOTAL REVENUES $58.67 MILLION VERSUS $18.17 MILLION.  Full Article

Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Beigene Ltd <6160.HK>::HILLHOUSE CAPITAL MANAGEMENT, LTD. REPORTS 1.7 PERCENT STAKE IN BEIGENE LTD AS OF JANUARY 1 - SEC FILING.HILLHOUSE CAPITAL MANAGEMENT, LTD. PREVIOUSLY REPORTED 9.29 PERCENT STAKE IN BEIGENE LTD AS OF FEBRUARY 8, 2016.  Full Article

Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Beigene Ltd <6160.HK>::ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND LICENSE AGREEMENT FOR ZYMEWORKS’ AZYMETRIC™ AND EFECT™ PLATFORMS GLOBALLY.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE TOTAL UPFRONT PAYMENTS OF US$40 MILLION UNDER ZW25 AND ZW49 AGREEMENTS AND US$20 MILLION UNDER PLATFORM AGREEMENT.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE DEVELOPMENT AND COMMERCIAL RIGHTS TO ZYMEWORKS' BISPECIFIC CANDIDATES, ZW25 AND ZW49, IN ASIA.ZYMEWORKS INC - BEIGENE ALSO ACQUIRES LICENSES FOR ZYMEWORKS' AZYMETRIC AND EFECT PLATFORMS.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE RIGHTS TO ZW25 AND ZW49, IN ASIA (EXCLUDING JAPAN), AUSTRALIA, AND NEW ZEALAND.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS PLUS POTENTIAL ROYALTIES ON PRODUCT SALES..ZYMEWORKS - IS ELIGIBLE TO RECEIVE UP TO US$390 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR BOTH PRODUCT CANDIDATES.ZYMEWORKS - UNDER TERMS OF AGREEMENT FOR AZYMETRIC AND EFECT PLATFORMS, CO ELIGIBLE TO RECEIVE UP TO AN AGGREGATE OF US$702 MILLION IN MILESTONE PAYMENTS.ZYMEWORKS - ELIGIBLE TO GET UPTO $702 MILLION IN DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS FOR UP TO 3 BISPECIFIC PRODUCT CANDIDATES DEVELOPED.  Full Article